Approved Drug Products of Vertex Pharmaceuticals listed in the FDA Orange Book.

May 1, 2023 BOSTON -- (BUSINESS WIRE)--May 1, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq VRTX) today reported consolidated financial results for the first quarter ended March 31, 2023 and reiterated full year 2023 financial guidance.

. At Vertex, we invest in scientific innovation to create transformative medicines for people with serious diseases.


85, -5.

com. stomach (abdominal) pain. .


. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. .

05 a share exceeded Wall Street views of 2. Fourth-Quarter Results.

Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals discovers, develops and commercializes pharmaceutical products for treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease and neurological disorders.

ET. 20.

. Number of Exits 2.

The Company&39;s strategy is to commercialize its products both independently and in collaboration with major.
Our scientists dont see the impossible as an obstacle; they see it as a good place to start.
Vertex Pharmaceuticals Incorporat.

10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close.


. . Vertex GPS offers eligible patients personalized, one-on-one support from day 1.

The company will host a conference call and webcast at 430 p. com. . Vertex&39;s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, and pain and bacterial. . May 18, 2023 5 stocks we like better than Vertex Pharmaceuticals.


Jan 18, 2023 Vertex Pharmaceuticals (VRTX 0. S.

Net income of 3.



Through our transformative medicines for patients, we drive value for our company, shareholders and society.

Jan 10, 2022 Recent Results.